BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients. 1988

H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
First Department of Medicine, Osaka University Medical School, Japan.

We examined the response of 8 patients with nephrotic syndrome (creatinine clearance 70.4 +/- 16.0 ml/min) to oral furosemide (F; 40 mg) in the absence (control) and in the presence of oral hydrochlorothiazide (HCT; 100 mg). In the 24-hour period after oral F, HCT was shown to increase urine volume and urinary sodium and chloride excretion. Increment was most significant during the 12- to 24-hour period. Enhancement of the diuresis with HCT was associated neither with a significant increase in the area under the curve of plasma F concentration nor an increase in urinary F excretion. Urinary excretion of glucuronidated F, one of the main metabolites of F, however, was decreased with HCT. In summary, HCT significantly enhanced the response to F in nephrotic patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009404 Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction. Childhood Idiopathic Nephrotic Syndrome,Frequently Relapsing Nephrotic Syndrome,Multi-Drug Resistant Nephrotic Syndrome,Pediatric Idiopathic Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndrome,Steroid-Resistant Nephrotic Syndrome,Steroid-Sensitive Nephrotic Syndrome,Multi Drug Resistant Nephrotic Syndrome,Nephrotic Syndrome, Steroid-Dependent,Nephrotic Syndrome, Steroid-Resistant,Nephrotic Syndrome, Steroid-Sensitive,Nephrotic Syndromes,Steroid Dependent Nephrotic Syndrome,Steroid Resistant Nephrotic Syndrome,Steroid Sensitive Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndromes,Steroid-Resistant Nephrotic Syndromes,Steroid-Sensitive Nephrotic Syndromes,Syndrome, Nephrotic,Syndrome, Steroid-Sensitive Nephrotic
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005260 Female Females
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006852 Hydrochlorothiazide A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. Dichlothiazide,Dihydrochlorothiazide,Esidrex,Esidrix,HCTZ,HydroDIURIL,Hypothiazide,Oretic,Sectrazide

Related Publications

H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
August 2007, Journal of cardiovascular pharmacology,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man.
October 1985, European journal of clinical investigation,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs.
December 2005, Journal of cardiovascular pharmacology,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Bioequivalence between two furosemide-spironolactone formulations: a pharmacokinetic and pharmacodynamic approach.
January 1991, Current medical research and opinion,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacokinetic and pharmacodynamic interactions between opioids and propofol.
September 1997, Journal of clinical anesthesia,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.
January 1988, Clinical pharmacology and therapeutics,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil.
October 1987, The Journal of pharmacology and experimental therapeutics,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacokinetic and pharmacodynamic interactions between caffeine and diazepam.
April 1986, Journal of clinical psychopharmacology,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacodynamic and pharmacokinetic interactions between ketamine and diazepam.
January 1983, European journal of clinical pharmacology,
H Nakahama, and Y Orita, and M Yamazaki, and S Itoh, and T Okuda, and A Yamaji, and Y Miwa, and M Yanase, and Y Fukuhara, and T Kamada
Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.
September 1996, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!